MarketPeel
Insider Trading Intelligence
Pricing
…
TW

Timothy Williams

VNDA
SVP & GENERAL COUNSEL · VANDA PHARMACEUTICALS INC. · CIK 0001748392
FILING MIX · LIFETIME39%/61%
BUYS
12
SELLS
19
TOTAL VALUE
$1.64M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
2,877,450
AVG SELL PX
$8.96
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Timothy Williams, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+77.78%-2.28%-1.52%-0.76%-0.07%—
14d18+66.67%-4.44%-2.35%-2.09%-2.79%—
30d18+61.11%-2.71%-1.02%-1.69%+3.37%—
60d18+55.56%-1.63%+0.49%-2.12%-2.97%—
90d18+55.56%-0.78%+2.89%-2.48%-6.35%—
180d18(1 pending)+82.35%-7.20%+10.13%-17.33%-24.12%—
1y18(1 pending)+70.59%-13.68%+16.75%-30.43%-48.05%—
2y18(1 pending)+82.35%-25.19%+30.25%-55.44%-71.26%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VNDA · 377,450 shares · as of Mar 2, 2026
0104,971209,942314,913419,884202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 19 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GERN
GERON CORP
PURCHASEGRANT
Stock grant
2,500,000——2,500,000Apr 13, 2026Apr 14, 2026 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
42,434$8.27$350.8K377,450Mar 2, 2026Mar 4, 2026 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000——419,884Feb 18, 2026Feb 19, 2026 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
26,941$4.76$128.2K294,884Mar 1, 2025Mar 4, 2025 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000——321,825Feb 18, 2025Feb 20, 2025 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
8,941$4.18$37.4K196,825Mar 5, 2024Mar 6, 2024 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
8,147$4.41$35.9K205,766Mar 4, 2024Mar 6, 2024 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000——213,913Feb 16, 2024Feb 21, 2024 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
14,600$6.56$95.8K88,913Jun 13, 2023Jun 15, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
8,301$6.25$51.9K103,513Mar 3, 2023Mar 6, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
8,437$6.24$52.7K111,814Mar 2, 2023Mar 6, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
32,700——120,251Feb 16, 2023Feb 21, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,500——77,500Feb 16, 2023Feb 21, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
8,000$7.01$56.1K87,551Dec 15, 2022Dec 16, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
3,689$10.42$38.4K100,162Aug 15, 2022Aug 17, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
4,611$10.21$47.1K95,551Aug 15, 2022Aug 17, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
12,060$11.09$133.8K103,851Mar 2, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
32,700——115,911Feb 28, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,500——77,500Feb 28, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
3,715$16.15$60.0K83,211Aug 16, 2021Aug 17, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
5,400$17.85$96.4K86,926Mar 5, 2021Mar 8, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
200$17.88$3.6K92,326Mar 5, 2021Mar 8, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
7,674$18.54$142.3K92,526Mar 2, 2021Mar 3, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
11,856$18.60$220.5K100,200Mar 1, 2021Mar 3, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,500——77,500Feb 24, 2021Feb 26, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
32,700——112,056Feb 24, 2021Feb 26, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
3,684$11.81$43.5K79,356Aug 14, 2020Aug 17, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
1,237$10.51$13.0K83,040Mar 3, 2020Mar 3, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP & General Counsel
3,148$10.30$32.4K84,277Mar 2, 2020Mar 3, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
30,000——87,425Feb 26, 2020Feb 28, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
70,000——70,000Feb 26, 2020Feb 28, 2020 ↗View →
Other insiders · VNDA
Loading peer insiders…
About this filer
CIK 0001748392
ROLE
SVP & General Counsel
PRIMARY
VNDA
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001748392DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback